The effect of timolol drops on respiratory function Abstract Purpose Recently, attention has been focused on the adverse drug reactions of topical timolol, especially with regard to respiratory function in the elderly. This study was
Results Two hours after instillation of timolol there was no change in PFR ( p = 0.67) or ve ( p = 0.40), but there was a fall in FEV ( p = 0.038) and the FEV/Ve (%) ratio ( p = 0.041).
The fall was greatest after topical administration.
Conclusions Our results show that in our group of patients there was a tendency towards mild bronchial obstruction after topical timolol, although this was not clinically significant. whether timolol caused an alteration in the lung function of patients who had never previously received ocular hypotensive medication, did not have pre-existing respiratory disease on direct questioning, and who had not suffered the impact of long-term �2 blockade.
Materials and methods
A placebo-controlled, randomised, double masked, cross-over study was designed to compare the effect on respiratory function of timolol 0.5% drops given sublingually or systemically (sublingually). The comparison of the effects of these routes of administration on intraocular pressure in 12 ocular hypertensive patients has been reported previously? On the basis of the data published by Diggory et al.,1 for this study to have 80% power to detect a mean change in forced expiratory volume in 1 s (FEV) of 0.25 with a significance level of 5%, 20 patients were required?
Ethics committee approval was obtained before commencement of the study. After appropriate explanation and informed consent, 20 ocular hypertensive patients (mean age 59.1 years, range 41-87 years) with intraocular pressure (lOP) over 21 mmHg, normal optic discs and full visual fields by Humphrey perimetry, were recruited. Patients were excluded if they were already using topical IOP lowering agents, being treated with systemic beta-blockers or calcium channel blockers, were known to suffer from systemic hypertension, asthma, bronchitis, cardiac failure, sinus bradycardia or heart block, or were smokers.
For each arm of the study, peak expiratory flow rate (PFR), FEV and vital capacity (VC) were measured between 0900 and 0930 hours before instillation of the test drop. From these values, the FEV Ive (%) ratio was calculated. The four arms, each separated by a minimum of 7 days and performed in random order, consisted of ocular instillation of timolol or placebo, and systemic (sublingual) instillation of timolol or placebo. Ocular instillation was followed by puncta I occlusion for 60 s. The systemic drop was placed at the base of the tongue and the patient asked not to swallow for Respiratory function measurements were conducted by the cardiac department at the Queen's Medical Centre using a spirometer (Vitalograph, UK). The technicians were masked to the site and type of drop used for each patient. Randomisation for the cross-over was performed by the picking of folded labels on which were written the site of treatment and solution. to be used.
Results
Twenty patients (11 women, 9 men) completed the four arms of the study. Two-way analysis of variance was used to analyse baseline values (pre-treatment) of the four outcome measures (VC, FEV, FEV IVC and PFR) for the four treatment groups. Results are presented in Table  1 . There was no significant difference between the treatment groups regarding baseline values for any of the four outcome measures. Two-way analysis of variance was used to analyse the differences (post-treatment minus pre-treatment) of the four outcome measures for the four treatment groups. Results are presented in Table  2 . There was a significant difference between the treatment groups for the outcomes FEV (p = 0.038) and FEV IVC (p = 0.041), but not for PFR (p = 0.67) or VC (p = 0.40). Three pairwise comparisons were carried out: treatment group 1 versus 3, group 2 versus 4, and group 3 versus 4. Adjustment of the p values to take into account multiple comparisons is required. Results are presented in Table 3 . This shows that there is a significantly greater fall in FEV and FEV Ive when timolol is given topically than when it is given systemically.
Discussion
The use of beta-blockers is common in many specialities. Indeed, Graft et al? reported that 1.4% of patients of all ages were prescribed oral or topical beta-blockers in a 1 year period, and that the frequency of beta-blocker prescriptions increases with patient age. Epidemiological studies have shown that there may be a 37% prevalence of airway obstruction in the over-65 age group.4 It is beyond debate that non-selective beta-blockers should not be used in patients with obstructive airways disease, but despite this 8.9% of asthmatics aged between 60 and 69 years had received beta-blockers.3 Although ophthalmologists should check for contraindications to the use of beta-blockers before a newly diagnosed glaucoma patient is started on such treatment, it is probably less usual for questions to be asked concerning the presence of side effects when the lOPs have been stabilised on beta-blockers, unless the patient volunteers the information. Spaeth and Birbilis5 found that less than 10% of patients admitted adverse reactions to ocular drugs On general questioning, but this increased to over 30% when mention was made of specific symptoms. As well as adverse drug reactions affecting the respiratory system, there is potential for serious cardiovascular side effects (bradycardia, congestive cardiac failure, arrhythmia, syncope) and central nervous system side effects (depression, hallucination, psychosis, confusion, insomnia, fatigue), 6 and these probably occur more commonly than ophthalmologists would like to think.
Recent work has highlighted the potential for serious respiratory side effects in the elderly. 1 Diggory et al. 1 showed that 19 of 47 elderly patients who were changed from topical timolol to either pilocarpine or betaxolol showed an increase in all of the three indices measured, i.e. PFR, FEV and Vc. Although all these results were highly significant on their own, interpretation of the increases in PFR and FEV is less useful without regard to the ve, which usually takes the form of the FEV Ive (%) ratio. With knowledge of baseline airway fUnction, if the FEV Ive (%) ratio falls, then this usually indicates an obstructive airways problem? Returning to the results of Diggory's group, we notice little change in the FEV Ive (%) ratio, and in fact statistical testing reveals the changes not to be significant. 1 The side effects of topical timolol in the elderly may be explained by timolol's strong and long-lasting beta receptor antagonism, even after a single dose.8 After a 40 fLl dose of timolol 0.25% in each eye of elderly patients undergoing cataract extraction, timolol was rapidly absorbed into the systemic circulation, occupying up to 68% of 13 1 receptors and up to 87% of 132 receptors. The 13 1 and 132 receptor occupancy decreased slowly and was 38% and 64% respectively 12 h after the single dose; the mean half-life was 4.8 h. Both values were twice as high as those found in healthy young volunteers following an intravenous dose of timolol 0.25 mg. For the purpose of our study, a separation period of 7 days between each visit was felt to be adequate as we were only using a single rather than a cumulative dose of timolol, and so we did not expect any prolonged beta-receptor antagonism.
Our study does seem to agree with previous work, as our results do show mild respiratory obstruction. The change is mild because there was not a significant fall in PFR but there was a significant fall in the FEV Ive (%) ratio? This was the case after the instillation of topical timolol, which is the usual route of administration for glaucoma patients, but not after systemic delivery of timolol. We are unable fully to explain this difference between the two routes of administration. We had expected that any change in respiratory function would be greater after systemic timolol because the sublingual route of administration should lead to the rapid absorption of a higher dose of timolol into the plasma, and it is the plasma timolol that is responsible for the (respiratory and other) side effects. First pass metabolism of timolol by the liver accounts for at least 25% of an administered oral dose,9 and the lOP reductions we obtained after sublingual administration in our original study were probably because maximum plasma levels are obtained rapidly after absorption through the buccal mucosa, leading to early receptor blockade before drug metabolism can occur? This may also account for the fact that these beta-antagonist effects were obtained with a relatively small dose of timolol (35 fLl of a 0.5% solution) compared with the larger oral doses of timolol used in previous studies.
We tried to reduce the absorption of timolol entering the systemic circulation after ocular instillation (and thus tried to separate local from general effects) by observing strict occlusion of the lacrimal punctum after both the ocular doses. It has previously been shown that systemic drug absorption is reduced (although not abolished) after instillation of topical timolol 0.5')10 if the eyes are closed or the lacrimal punctum is occluded.
III It would have been ideal in a study such as this to be able to measure the plasma levels of timolol after both the topical and sublingual doses, as well as in patients who may be suffering side effects attributable to timolol. Unfortunately, the measurement of plasma timolol is difficult, time-consuming and expensive, and is probably beyond the expertise of most clinical ophthalmology departments. These methods have a lower detection limit of timolol of 1-2 nglml, and so levels in patients even after 2 weeks of twice daily timolol 0.5% may not even be detectable.9,11
The above results, although statistically Significant, may not necessarily be clinically significant, especially when considering the variability in respiratory function measurements (up to 10%). It is reassuring that there was no reduction in PFR, which indicates that there was no intrinsic airway disease? There was a reduction in the FEV IVC (%) ratio, indicating mild respiratory obstruction. Much greater reductions in these indices (around 20%) would be required to have a clinically significant effect on lung function and thus cause a patient to be symptomatic. Certainly none of our study patients reported any respiratory problems on direct questioning at the end of each treatment session.
Our results show that, at least 2 h after a single dose of topical timolol, and in patients who are otherwise healthy and without pre-existing respiratory problems, there does seem to be a tendency towards bronchial obstruction, although this is not clinically significant. It was also encouraging that there was no bronchoconstriction after systemic timolol. However, this is a small pilot study, and we feel that further investigation into respiratory effects is warranted, in particular to investigate whether long-term usage of beta-blockers induces bronchoconstriction in a similar group of 'low' -risk patients. This should be done with a knowledge of baseline respiratory function before beta blockade is initiated. Greater importance should be attached to the identification of the many other adverse reactions of timolol, and similar effort should be made in investigating and reducing these also.
